



Press release

STADA further improves Sustainability Ranking again; rates among top 6% of pharma players globally

- STADA further improves independent sustainability ranking; Sustainalytics ESG Risk Rating puts STADA among top 6% of pharma firms globally
- Sustainalytics: "STADA Arzneimittel AG's management of ESG material risk is strong"
- STADA CEO Peter Goldschmidt: "STADA's ongoing commitment to further driving sustainability across all our activities reflects the Group's overarching purpose of Caring for People's Health as a Trusted Partner"

Bad Vilbel – 12 December 2023 – STADA is among the most sustainable pharmaceutical companies globally, an independent assessment has confirmed. Assessing STADA for the first time as "low risk" in its Environmental, Social and Governance (ESG) Risk Ratings, independent agency Sustainalytics ranked STADA among the top 6% of all companies within its Pharmaceuticals sector comprising almost 900 companies appraised in terms of ESG risk.

"STADA Arzneimittel AG's management of ESG material risk is strong," Sustainalytics stated in improving STADA's risk rating from 22.2, or "medium risk" in December 2022, to 18.4, or "low risk", in December 2023¹. This assessment is based on a comprehensive framework of more than 70 management indicators that are designed to provide an in-depth analysis of a company's ESG strengths and weaknesses compared to its competitors and the overall industry performance.

¹ [STADA Arzneimittel AG ESG Risk Rating \(sustainalytics.com\)](https://www.sustainalytics.com/ratings/stada-arzneimittel-ag-esg-risk-rating)



This improved ranking places STADA 48th within the Pharmaceuticals cohort of 885 companies. Furthermore, STADA is ranked among the top quartile of the global universe of more than 15,000 organizations evaluated by Sustainalytics.

In particular, Sustainalytics assessed as “strong” STADA’s risk management in terms of: product governance; business ethics; corporate governance; emissions, effluent and waste; carbon from own operations; and bribery and corruption.

“It is gratifying that Sustainalytics has independently recognized the multiple initiatives STADA is implementing across diverse ESG topics,” commented STADA CEO Peter Goldschmidt. “Our ongoing commitment to further driving sustainability across all our activities reflects the Group’s overarching purpose of Caring for People’s Health as a Trusted Partner.”

STADA’s ESG initiatives and activities that contributed to the improved Sustainalytics rating, as well as progress on supporting United Nations Sustainable Development Goals to which the company is a signatory, are detailed in the Group’s Sustainability Report 2022².

The Group continues to strive towards decarbonization, such as by using renewable energy. For example, greenhouse gas (GHC) emissions have reduced by 16.5% since 2020. As a supplier of around 1.2 billion medicines packs per year, STADA makes a significant contribution to affordable access to medicines. The Group is also committed to being a responsible and equitable employer, with a 53% share of women in management positions.

Further promoting diversity and uniqueness, as well as equal pay and fair working conditions, are among STADA’s priorities as the group continues its sustainability journey. The group continues to make progress with its access to medicines programme and to invest

² [STADA Sustainability Report 2022 \(Pdf\)](#)



in an environmentally-responsible supply chain, such as through a supply-chain hub currently being constructed in Turda, Romania, using ecologically-friendly technologies such as photovoltaic solar panels and low-energy lighting. Reducing 'Scope 3' carbon emissions remains a central focus of STADA's sustainability initiatives.

Copyright ©2022 Sustainalytics. All rights reserved.

This press release contains information developed by Sustainalytics (www.sustainalytics.com). Such information and data are proprietary of Sustainalytics and/or its third party suppliers (Third Party Data) and are provided for informational purposes only. They do not constitute an endorsement of any product or project, nor an investment advice and are not warranted to be complete, timely, accurate or suitable for a particular purpose. Their use is subject to conditions available at <https://www.sustainalytics.com/legal-disclaimers>.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2022, STADA achieved group sales of EUR 3,797.2 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of 31 December 2022, STADA employed 13,183 people worldwide.

About Sustainalytics' ESG Research and Ratings

Sustainalytics' ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks. This multi-dimensional way of measuring ESG risk combines the concepts of management and exposure to arrive at an assessment of ESG risk, i.e. a total unmanaged ESG risk score or the ESG Risk Rating, that is comparable across all industries. Sustainalytics' ESG Risk Ratings provide a quantitative measure of unmanaged ESG risk and distinguish between five levels of risk: negligible, low, medium, high and severe. Learn more about the ESG Risk Ratings [here](#).

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au



About Sustainalytics

Sustainalytics, a Morningstar company, is a leading independent ESG research, ratings and data firm that supports investors around the world with the development and implementation of responsible investment strategies. Sustainalytics works with hundreds of the world's leading asset managers and pension funds who incorporate ESG and corporate governance information and assessments into their investment processes. The firm also works with hundreds of companies and their financial intermediaries to help them consider sustainability in policies, practices and capital projects. For more information, visit www.sustainalytics.com.

Additional information for journalists:

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18

61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Follow STADA on [LinkedIn](#)

Additional information for capital market participants:

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18

61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler

Chairman of the Supervisory Board: Dr. Günter von Au